Background and design of the clinical study with tasquinimod in relapsed or refractory multiple myeloma will be presented at the virtual American Society of Hematology meeting December 5, 2020 – A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma. Dan T. Vogl, MD, Yulia Nefedova, MD, E. Paul Wileyto, Harjeet Sembhi, Inna Strakovsky, Chau Nguyen, Rimzim Taneja, Eva Bondesson, Helena Eriksson and Helen Tuvesson – Read the abstract here.